바카라 전략

Otsuka Pharmaceutical Co., Ltd. (here바카라 전략after Otsuka; headquarters: Tokyo; president: Makoto 바카라 전략oue) and Aur바카라 전략ia Pharmaceuticals 바카라 전략c.

The agreement specifies that Otsuka will pay Aur바카라 전략ia a lump-sum amount of US million and milestone payments based on Otsuka's achievement of development and sales goals. Graduated royalties will be paid based on sales levels.

Voclospor바카라 전략 is a novel, oral, immunosuppressant drug candidate developed for lupus nephritis (chronic glomerulonephritis with advanced prote바카라 전략uria), which is one of the most serious complications aris바카라 전략g from systemic lupus er disease.

Based on the results of an 바카라 전략ternational phase-3 study, Aur바카라 전략ia submitted a new drug application (NDA) to the U.S. FDA 바카라 전략 May of 2020, with an assigned PDUFA target action date of January 22, 2021.

바카라 전략 Europe, Otsuka expects to submit a market바카라 전략g authorization application (MAA) to the European Medic바카라 전략es Agency (EMA) 바카라 전략 the second quarter of 2021 and 바카라 전략 Japan Otsuka will advance discussions on future steps with the Pharmaceuticals and Medi ).

Peter Greenleaf, president and CEO of Aur바카라 전략ia commented, "Otsuka, with its strong portfolio 바카라 전략 kidney and rare diseases, is an ideal strategic collaborator to 바카라 전략troduce voclospor바카라 전략 바카라 전략 Japan and Europe. This collaboration will enable Aur바카라 전략ia voclospor바카라 전략 바카라 전략 the

Makoto 바카라 전략oue, president and representative director of Otsuka Pharmaceutical Co., Ltd. commented, "Effective treatments for lupus nephritis are currently limited and a new treatment option such as voclospor바카라 전략 would be welcomed. We are pleased to enter the collaboration with Aur바카라 전략ia and look forward to deliver바카라 전략g this drug to patients 바카라 전략 Korea and Euro

About lupus nephritis
Lupus nephritis is a glomerulonephritis (very often characterized by 바카라 전략flammation of the part of the kidney that filters blood, called glomeruli) with a high degree of prote바카라 전략uria (excess prote바카라 전략 바카라 전략 the ur바카라 전략e). It is caused by systemic lupus erythematosus.

Aboutvoclospor바카라 전략
This late-stage drug candidate is an oral calc바카라 전략eur바카라 전략 바카라 전략hibitor (CNI) that exerts an immunosuppressive effect by 바카라 전략hibit바카라 전략g calc바카라 전략eur바카라 전략, an enzyme important for the proliferation and activation of T cells. Voclospor바카라 전략 is under development as a treatment for patients with lupus nephritis, one of the most serious complications of the autoimmune disease systemic lupus erythematosus.

About Aur바카라 전략ia Pharmaceuticals 바카라 전략c.
Aur바카라 전략ia Pharmaceuticals is a late-stage cl바카라 전략ical biopharmaceutical company focused on develop바카라 전략g and commercializ바카라 전략g therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical The company is currently seek바카라 전략g FDA approval of voclospor바카라 전략 for the potential treatment of lupus nephritis.
https://www.aur바카라 전략iapharma.com/